Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells

Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ <i>neu</i> Oncogene

Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760 · see citing works

Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer

Vogel, C. L., Cobleigh, M., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.3.719 · Cited by 3,240 · see citing works

Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease

Cobleigh, M., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V. E., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,767 · see citing works

Humanization of an anti-p185HER2 antibody for human cancer therapy.

Carter, P., Presta, L., Gorman, C., Ridgway, J., Henner, D., Wong, W., Rowland, A., Kotts, C., Carver, M. E., & Shepard, H. (1992) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.89.10.4285 · Cited by 1,958 · see citing works

Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of <i>HER2</i>-Overexpressing Metastatic Breast Cancer

Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.719 · Cited by 1,860 · see citing works

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients

Nagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.022 · Cited by 1,858 · see citing works

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.

Baselga, J. M., Tripathy, D., Mendelsohn, J. M., Baughman, S. A., Benz, C. C., Dantis, L., Sklarin, N. T., Seidman, A. D., Hudis, C. A., Moore, J. L., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.3.737 · Cited by 1,382 · see citing works

Insulin-Like Growth Factor-I Receptor Signaling and Resistance to Trastuzumab (Herceptin)

Lu, Y., Zi, X., Zhao, Y., Mascarenhas, D. D., & Pollak, M. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.24.1852 · Cited by 884 · see citing works

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth

Agus, D. B., Akita, R. W., Fox, W. D., Lewis, G. D., Higgins, B., Pisacane, P. I., Lofgren, J. A., Tindell, C., Evans, D. P., Maiese, K., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00097-1 · Cited by 873 · see citing works

The HER-2-Targeting Antibodies Trastuzumab and Pertuzumab Synergistically Inhibit the Survival of Breast Cancer Cells

Nahta, R., Hung, M., & Esteva, F. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3856 · Cited by 607 · see citing works

Phase II Study of Weekly Docetaxel and Trastuzumab for Patients With HER-2–Overexpressing Metastatic Breast Cancer

Esteva, F. J., Valero, V., Booser, D. J., Guerra, L. T., Murray, J. L., Pusztai, L., Cristofanilli, M., Arun, B., Esmaeli, B., Fritsche, H. A., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.07.058 · Cited by 566 · see citing works

Decreased Accessibility and Lack of Activation of ErbB2 in JIMT-1, a Herceptin-Resistant, MUC4-Expressing Breast Cancer Cell Line

Nagy, P., Friedländer, E., Tanner, M., Kapanen, A. I., Carraway, K. L., Isola, J. J., & Jovin, T. M. (2005) · Cancer Research · doi:10.1158/0008-5472.473.65.2 · Cited by 525 · see citing works

P27kip1 Down-Regulation Is Associated with Trastuzumab Resistance in Breast Cancer Cells

Nahta, R., Takahashi, T., Ueno, N. T., Hung, M.-C., & Esteva, F. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3900 · Cited by 298 · see citing works

Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer

Tanner, M., Kapanen, A. I., Junttila, T. T., Raheem, O., Grénman, S., Elo, J. P., Elenius, K., & Isola, J. J. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1585.3.12 · Cited by 272 · see citing works

The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.

Motoyama, A. B., Hynes, N. E., & Lane, H. A. (2002) · PubMed · Cited by 249 · see citing works

Growth inhibition of human breast cancer cells in vitro with an antibody against the type I somatomedin receptor.

Arteaga, C. L., & Osborne, C. K. (1989) · PubMed · Cited by 234 · see citing works

Molecular mechanisms underlying IGF‐I‐induced attenuation of the growth‐inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells

Lu, Y., Zi, X., & Pollak, M. (2003) · International Journal of Cancer · doi:10.1002/ijc.11445 · Cited by 206 · see citing works

Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.

Diermeier, S., Horvath, G. L., Knuechel-Clarke, R., Hofstaedter, F., Szöllősi, J., & Brockhoff, G. (2005) · Experimental Cell Research · doi:10.1016/j.yexcr.2004.12.008 · Cited by 192 · see citing works

The Role of Cyclin-dependent Kinase Inhibitor p27Kip1 in Anti-HER2 Antibody-induced G1 Cell Cycle Arrest and Tumor Growth Inhibition

Le, X., Claret, F.-X., Lammayot, A., Tian, L., Deshpande, D. M., LaPushin, R., Tari, A. M., & Bast, R. C. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300848200 · Cited by 151 · see citing works

Modulation of p27/Cdk2 complex formation through 4D5-mediated inhibition of HER2 receptor signaling

Lane, H. A., Motoyama, A. B., Beuvink, I., et al. (2001) · Annals of Oncology · doi:10.1093/annonc/12.suppl_1.s21 · Cited by 119 · see citing works

Activation of ErbB-2 via a hierarchical interaction between ErbB-2 and type I insulin-like growth factor receptor in mammary tumor cells

Balañá, M. E., Labriola, L., Salatino, M., et al. (2001) · Oncogene · doi:10.1038/sj.onc.1204050 · Cited by 119 · see citing works

Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin

Anastasi, S., Sala, G., Huiping, C., Caprini, E., Russo, G., Iacovelli, S., Lucini, F., Ingvarsson, S., & Segatto, O. (2005) · Oncogene · doi:10.1038/sj.onc.1208658 · Cited by 115 · see citing works

Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells.

Camirand, A., Lu, Y., & Pollak, M. (2002) · PubMed · Cited by 98 · see citing works

Unraveling Resistance to Trastuzumab (Herceptin): Insulin-Like Growth Factor-I Receptor, a New Suspect

Albanell, J., & Baselga, J. M. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.24.1830 · Cited by 88 · see citing works

New mechanisms of signal transduction inhibitor action: receptor tyrosine kinase down-regulation and blockade of signal transactivation.

Lee, A. V., Schiff, R., Cui, X., et al. (2003) · PubMed · Cited by 17 · see citing works

ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics

Arteaga, C. L., & Engelman, J. A. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.025 · Cited by 1,048 · see citing works

Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways

Zhang, S., Huang, W.-C., Li, P., Guo, H., Poh, S.-B., Brady, S. W., Xiong, Y., Tseng, L.-M., Li, S.-H., Ding, Z., et al. (2011) · Nature Medicine · doi:10.1038/nm.2309 · Cited by 515 · see citing works

Human Breast Cancer Cells Selected for Resistance to Trastuzumab <i>In vivo</i> Overexpress Epidermal Growth Factor Receptor and ErbB Ligands and Remain Dependent on the ErbB Receptor Network

Ritter, C. A., Perez-Torres, M., Rinehart, C., Guix, M., Dugger, T., Engelman, J. A., & Arteaga, C. L. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0701 · Cited by 497 · see citing works

Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells

Shattuck, D. L., Miller, J. K., Carraway, K. L., & Sweeney, C. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5962 · Cited by 473 · see citing works

A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer

Xia, W., Bacus, S., Hegde, P., Husain, I., Strum, J., Liu, L., Paulazzo, G., Lyass, L., Trusk, P., Hill, J., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0602468103 · Cited by 374 · see citing works

Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2 ⁺ breast cancer patients

Scaltriti, M., Eichhorn, P. J., Cortés, J., Prudkin, L., Aura, C., Jiménez, J., Chandarlapaty, S., Serra, V., Prat, A., Ibrahim, Y. H., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014835108 · Cited by 337 · see citing works

Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling

Nahta, R., Yuan, L. X. H., Du, Y., & Esteva, F. J. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0423 · Cited by 267 · see citing works

Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers

Dave, B., Migliaccio, I., Gutierrez, M. C., Wu, M.-F., Chamness, G. C., Wong, H., Narasanna, A., Chakrabarty, A., Hilsenbeck, S. G., Huang, J., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.7814 · Cited by 252 · see citing works

Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer

Harris, L. N., You, F., Schnitt, S. J., Witkiewicz, A., Lu, X., Sgroi, D., Ryan, P. D., Come, S. E., Burstein, H. J., Lesnikoski, B.-A., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1304 · Cited by 245 · see citing works

Activin A more prominently regulates muscle mass in primates than does GDF8

Latres, E., Mastaitis, J., Fury, W., Miloscio, L., Trejos, J., Pangilinan, J., Okamoto, H., Cavino, K., Na, E., Papatheodorou, A., et al. (2017) · Nature Communications · doi:10.1038/ncomms15153 · Cited by 185 · see citing works

Facts and controversies in the use of trastuzumab in the adjuvant setting

Dinh, P., de Azambuja, E., Cardoso, F., & Piccart-Gebhart, M. J. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1219 · Cited by 19 · see citing works

Phase II evaluation of the efficacy and safety of trastuzumab plus pertuzumab therapy in patients with HER2-positive metastatic breast cancer that had progressed during trastuzumab treatment

(2008) · doi:10.1016/s1359-6349(08)70882-6 · Cited by 1 · see citing works

A new anti-HER2 antibody that enhances the anti-tumor efficacy of trastuzumab and pertuzumab with a distinct mechanism of action

Zhang, X., Chen, J., Weng, Z., Li, Q., Zhao, L., Yu, N., Deng, L., Xu, W., Yang, Y., Zhu, Z., et al. (2020) · Molecular Immunology · doi:10.1016/j.molimm.2020.01.009 · Cited by 49 · see citing works

Pertuzumab (Perjeta®)

Garca‐Saénz, J. A., Antón, F. M., & Bueno, C. (2014) · doi:10.1002/9783527682423.ch67

Abstract 3477: Pertuzumab in combination with trastuzumab enhanced the anti-tumor activity in HER2-positive human gastric cancers

(2010) · doi:10.1158/1538-7445.am10-3477 · Cited by 3 · see citing works

Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer

Nami, B., Maadi, H., & Wang, Z. (2018) · Cancers · doi:10.3390/cancers10100342 · Cited by 192 · see citing works